Synechion Inc - TX Dallas, Dallas 75248

Synechion Inc entered the industry of Commercial Medical Research in 1996 and has grown to employ 1 to 4 people, generating an annual revenue of $500.000 to $999.999. The NAICS classifies this business under the code 541712, which describes it as a Commercial Medical Research. For further clarification, the SIC classifies this business under the code 8731 and described it as a Commercial Medical Research. The business provides service to the B2B market.

To acquire more information, please contact David Wiseman by calling (972) 931-5596 during business hours. You can also write to the business’ Single Location at 6757 Arapaho Road # 711, Dallas, Texas TX 75248. You can also visit the company’s website at adhesions.us. View this business’ social media profiles on Twitter or on Facebbok .

Company: Synechion Inc
Representative: David Wiseman
Place of Business: 6757 Arapaho Road # 711, Dallas, TX 75248
Contact Number: (972) 931-5596
Website: adhesions.us
Type of Service: Commercial Medical Research
SIC Number: 8731
NAICS Number: 541712
Locality: Single Location
Market Type: B2B (Business to Business)
Began: 1996
Income/Year: $500.000 to $999.999
Laborers: 1 to 4
Share This Company:

Synechion Inc is a company operating from Dallas, Texas providing professional Commercial Medical Research and relevant B2B variables. It was founded in 1996 and registered with the SIC code 8731 as Commercial Medical Research, and with the NAICS code 541712 as Commercial Medical Research.

With a current employee count of 1 to 4, Synechion Inc has gone to report making $500.000 to $999.999 per annum on its journey towards growth. This company invites you to contact its representative David Wiseman at (972) 931-5596 for related queries, or to locate its Single Location using the coordinates 32.96261,-96.791405.

The Single Location can also be found at the street address 6757 Arapaho Road # 711 in Dallas, Texas 75248 and can be engaged online through the company website at adhesions.us, the company Twitter , and Facebook page .